ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2021
Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Mechanical circulatory support for cardiogenic shock: a network meta-analysis of randomized controlled trials and propensity score-matched studies.Intensive care medicine · 2024Pooled it
- Extracorporeal membrane oxygenation for critically ill adults.The Cochrane database of systematic reviews · 2023Pooled it
- Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Trial
- Challenges of Intra-Aortic Balloon Pump and Extracorporeal Membrane Oxygenation in Cardiogenic Shock: Real-World Outcomes.Acta Cardiologica Sinica · 2026Article
- A nomogram for predicting intraoperative risk during primary percutaneous coronary intervention based on rapidly obtained data from ST-segment elevation myocardial infarction patients.Frontiers in cardiovascular medicine · 2026Article
- Extracorporeal Membrane Oxygenation in Acute Cardiovascular Care.Circulation reports · 2025Review
- Left ventricular unloading in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation.European heart journal open · 2025Article
- Treatment of Cardiogenic Shock and Refractory Ventricular Fibrillation: Pulling Out All the Stops.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Article
- Association Between Frailty and Management and Outcomes of Acute Myocardial Infarction Complicated by Cardiogenic Shock.JACC. Advances · 2024Article
- Sex-related differences in patients presenting with heart failure-related cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Observational
- Association between left ventricular ejection fraction, mortality and use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Management of cardiogenic shock: a narrative review.Annals of intensive care · 2024Review
- Extracorporeal Membrane Oxygenation.Respiratory care · 2023Review
- Management of Cardiogenic Shock: Present and Future.Texas Heart Institute journal · 2023Article
- Venting during venoarterial extracorporeal membrane oxygenation.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Review
- Contemporary Management of Cardiogenic Shock Complicating Acute Myocardial Infarction.Journal of clinical medicine · 2023Review
- An Evolving Roadmap for Cardiogenic Shock Requiring Temporary Mechanical Circulatory Support.JACC. Asia · 2023Article
- Aortic stenosis and mitral regurgitation modify the effect of venoarterial extracorporeal membrane oxygenation on left ventricular function in cardiogenic shock.Scientific reports · 2022Article
- PRospective REgistry of PAtients in REfractory cardiogenic shock-The PREPARE CardShock registry.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2022Article
- Interventional Cardiology: Current Challenges in Acute Myocardial Infarction.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCardiogenic shock (CGS) occurs in 6-10% of patients with acute coronary syndromes (ACS). Mortality has fallen over time from 80% to approximately 50% consequent on acute revascularisation but has plateaued since the 1990s. Once established, patients with CGS develop adverse compensatory mechanisms that contribute to the downward spiral towards death, which becomes difficult to reverse. We aimed to test in a robust, prospective, randomised controlled trial whether early support with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides clinical benefit by improving mortality and morbidity. METHODS AND
resultsThe EURO SHOCK trial will test the benefit or otherwise of mechanical cardiac support using VA-ECMO, initiated early after acute percutaneous coronary intervention (PCI) for CGS. The trial sets out to randomise 428 patients with CGS complicating ACS, following primary PCI (P-PCI), to either very early ECMO plus standard pharmacotherapy, or standard pharmacotherapy alone. It will be conducted in 39 European centres. The primary endpoint is 30-day all-cause mortality with key secondary endpoints: 1) 12-month all-cause mortality or admission for heart failure, 2) 12-month all-cause mortality, 3) 12-month admission for heart failure. Cost-effectiveness analysis (including quality of life measures) will be embedded. Mechanistic and hypothesis-generating substudies will be undertaken.
conclusionsThe EURO SHOCK trial will determine whether early initiation of VA-ECMO in patients presenting with ACS-CGS persisting after PCI improves mortality and morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.